Country: Canada
Language: English
Source: Health Canada
CLOPIDOGREL (CLOPIDOGREL BISULFATE)
MINT PHARMACEUTICALS INC
B01AC04
CLOPIDOGREL
75MG
TABLET
CLOPIDOGREL (CLOPIDOGREL BISULFATE) 75MG
ORAL
30/100
Prescription
PLATELET AGGREGATION INHIBITORS
Active ingredient group (AIG) number: 0134440001; AHFS:
APPROVED
2013-07-12
_MINT-CLOPIDOGREL (Clopidogrel Tablets) _ _Page 1 of 59 _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR MINT-CLOPIDOGREL Clopidogrel Tablets Tablets, 75 and 300 mg Clopidogrel, as clopidogrel bisulfate, Oral House Standard Platelet Aggregation Inhibitor Date of Initial Authorization: JUL 12, 2013 Date of Revision: APR 13, 2023 Mint Pharmaceuticals Inc. 6575 Davand Drive Mississauga, ON, L5T 2M3 Canada Submission Control No.: 273299 _MINT-CLOPIDOGREL (Clopidogrel Tablets) _ _Page 2 of 59 _ RECENT MAJOR LABEL CHANGES 7 WARNINGS AND PRECAUTIONS, Hematologic 04/2023 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES .......................................................................................... 2 TABLE OF CONTENTS .............................................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ................................................................... 4 1 INDICATIONS ............................................................................................................................ 4 1.1 Pediatrics ........................................................................................................................... 4 1.2 Geriatrics ............................................................................................................................ 4 2 CONTRAINDICATIONS............................................................................................................. 5 4 DOSAGE AND ADMINISTRATION ........................................................................................... 5 4.2 Recommended Dose and Dosage Adjustment ................................................................... 5 4.4 Administration ..................................................................................................................... 6 4.5 Missed Dose .............................. Read the complete document